10 results
To demonstrate non-inferiority in terms of neointimal coverage of Cre8 (CID) Drug Eluting Stent, evaluated at three months afterstent implantation, compared to Vision/Multilink 8 (Abbott) Bare Metal Stent evaluated at one month, in terms of…
* To evaluate the effectiveness of contemporary PCI treatment of de novo 3-vessel disease following the heart team selection applying the SYNTAX Score II with pressure wire functional assessment and IVUS guidance (SYNTAX II strategy).* To establish…
In the present study, we aim to perform a feasibility study to prove that 89Zirconium-bevacizumab PET scanning can indeed detect all small primary breast cancer lesions. Data from the present study may be used to design further studies with regard…
The primairy objective of this study is to evaluate the safety and efficacy of the Janus OPTIMA stent in the treatment of the novo lesions in native cotronary arteries with a maximum lenght of 28 mm and a diameter of 2.5 - 4.0 mm
To establish superiority of the biolimus-eluting (BiomatrixTM) stent compared with an otherwise identical bare-metal stent (GazelleTM) in acute ST-segment elevation myocardial infarction (STEMI) in terms of the composite endpoint of cardiac death,…
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with everolimus in patients with metastatic RCC. 89Zr-bevacizumab PET imaging will be regarded a promising…
ObjectiveTo investigate the performance of paclitaxel-coated balloon expandable stainless steel coronary stent for the treatment of infrapopliteal stenoses and occlusions in patients with critical limb ischemia compared to percutaneous transluminal…
The primary objective is to determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans. Secondary objectives are to explore if 89Zr-bevacizumab PET imaging can differentiate progressive from non-…
The aim of this feasibility study is to validate pre-treatment [89Zr]-bevacizumab PET/CT as an imaging biomarker for prediction of treatment response to bevacizumab treatment in patients with NF2 related (vestibular) schwannomas.
The primary objective is to establish the non-inferiority of the Synergy stent relative to the Xience stent for prevention of MACE. The effect measure is the difference in the rate of MACE in patients randomized to treatment with the Synergy ( index…